Bavarian Nordic Receives U.S. Funding for Expanded Smallpox Vaccine Production

Additional Vaccine Doses to be Manufactured for U.S. Strategic National Stockpile

Contract Includes Services for Storage and Maintenance of Vaccine

Bavarian Nordic AS has announced a new contract with the United States government, valued at $1568 million, to manufacture and supply additional smallpox vaccine doses for the U.S. Strategic National Stockpile.

Since 2003, Bavarian Nordic has collaborated with the U.S. government on the development, manufacturing, and supply of a non-replicating smallpox vaccine. This latest contract will enable the company to increase production of the vaccine, ensuring sufficient supply for national preparedness.

The contract also includes approximately $17 million for additional services in the period 2025-2027, including the storage and maintenance of vaccine doses in the U.S.